Expert Ratings for Sonnet BioTherapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for Sonnet BioTherapeutics (NASDAQ:SONN) within the last quarter, with an average 12-month price target of $10.22, a 47.59% decrease from the previous average price target of $19.50.
June 26, 2023 | 6:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sonnet BioTherapeutics received bullish ratings from analysts, with an average 12-month price target of $10.22, representing a 47.59% decrease from the previous target.
The bullish ratings from analysts indicate a positive outlook for Sonnet BioTherapeutics. However, the decrease in the average price target suggests that the stock may not perform as well as previously expected.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100